近日，据多位车主向北京商报记者反映，小鹏P7+转向机疑似接插件防水设计不足，水汽易侵入线束接 口，引发短路。不仅如此，面对数百条投诉，车主得到的售后方案却有着明显差异：部分可整体更换转 向机，部分仅能打胶处理，还有的因后台未显示问题被拒绝维修。即便能更换，小鹏方面的补偿方案也 并不一致。 这场打胶黏不住的信任危机，正在吞噬数万名车主的安全感。相关律师指出，选择性维修与责任推诿， 可能构成歧视性服务，侵犯消费者的公平交易权。同时，企业如果想以低成本替代方案规避召回责任， 则会面临更多违约风险。 随着对该车型的吐槽增多，浙江杭州的车主阳阳（化名）也在近期到当地小鹏4S店检查了车辆，发现 转向机被打胶后想拍照维权，却被4S店告知不允许拍照，她表示，购车时是4月，销售以"冲门店销 量"为由，劝其尽快付款，并给出了5月1日前付款提车补贴5000元现金和5000元京东卡的优惠，"但买后 半个月就从其他车主处了解到，5月产的新车都更换了转向机接口"。 有15年汽修经验的张先生向北京商报记者直言，转向机线束裸露并非正常现象，存在安全隐患。所 谓"打胶"是采用密封剂进行处理，"但这不能完全保证防水性，极端雨水天气或潮湿环境下， ...

2025年8月13日，双方自行和解或者投诉人撤回投诉。处理部门为：广州市黄埔区市场监督管理局。 天眼查商业履历信息显示，广州万孚生物技术股份有限公司成立于1992年11月13日，位于广州市黄埔区 科学城荔枝山路8号，是一家以从事研究和试验发展为主的企业，企业注册资本47134.2537万人民币， 法定代表人为王继华。 8月13日，根据全国12315消费投诉信息公示，广州万孚生物技术股份有限公司新增投诉。 根据投诉信息，2025年07月25日，消费者徐**（手机尾号 7252，用户ID ****4780）反映其于2025年07 月25日通过现场购买体外诊断试剂。可能存在质量->销售失效、变质的产品问题，要求赔偿损失，退赔 费用。 ...

Core Viewpoint - The Shanghai Market Supervision Administration is investigating Weitai Mei Company for alleged violations related to excessive lead content in its protein enzyme products, following consumer complaints [1][2]. Group 1: Investigation Details - A joint investigation team was established by the Shanghai Market Supervision Administration and Minhang District Government to thoroughly investigate the company and its products [1]. - The protein enzyme products were imported from Australia and were found to have lead contamination due to the ink layer on the glass droppers used for packaging [1]. - Both the protein enzyme and the accompanying plastic droppers tested negative for lead, but the glass droppers from Encheng Glass Processing Factory were found to have lead issues [1]. Group 2: Legal Actions and Company Response - The Minhang District Market Supervision Administration has initiated a formal investigation and has confiscated and removed the problematic products from the market [2]. - The Shanghai Public Security Bureau has also opened a criminal investigation into the company and the glass processing factory, with criminal measures taken against involved personnel [2]. - Weitai Mei Company has announced a recall of the affected product batches and is advising consumers to follow their official WeChat account for recall information [2].

Core Viewpoint - The company Romoss has announced a sudden suspension of operations for six months due to a product recall crisis, which has led to significant employee unrest and operational challenges [5][10]. Group 1: Company Operations - Romoss issued a notice on July 6, stating that it would suspend operations starting July 7 for six months, with only certain employees being recalled [5][10]. - The company has a history of high sales, reaching an annual shipment volume of 50 million units at its peak [9]. - The operational suspension has left many employees uncertain about their future, as they will only receive 80% of the local minimum wage after the first month of suspension [6][8]. Group 2: Product Recall and Crisis Management - The crisis began when Romoss faced a recall of 491,745 power bank units due to safety hazards, including risks of overheating and potential fire [9][10]. - The company’s initial response to the crisis was criticized for lacking systematic operation, leading to a collapse in consumer trust [10][12]. - The rapid changes in the company's legal representatives have raised concerns about potential attempts to evade responsibilities related to the crisis [10][12]. Group 3: Industry Context - The power bank industry is facing challenges related to product quality, particularly due to the use of low-cost battery cells that compromise safety [12]. - Romoss's reliance on low-cost components has been highlighted as a significant factor contributing to the current crisis, reflecting broader issues within the industry regarding supplier oversight and product safety [12].

Core Viewpoint - The company Romoss, a well-known power bank manufacturer, is facing significant operational challenges due to safety issues with its products, leading to a recall and suspension of sales across major e-commerce platforms [1][4]. Group 1: Product Issues and Recalls - Romoss has recalled 491,745 power banks due to safety concerns, which has resulted in the suspension of 3C certification for multiple fast-charging products [1]. - Following the recall announcement, customers reported difficulties in obtaining refunds, with some stating that the seller's account balance was insufficient to process returns [2]. Group 2: Operational Impact - As of July 1, 2023, Romoss has notified employees of a complete halt in production and operations, with wages only being paid up to June [4]. - On July 6, Romoss officially announced a six-month suspension of operations, during which employees will receive a portion of their wages based on local minimum wage standards [5][8]. Group 3: Employee Sentiment and Company Response - Employees expressed a range of emotions from surprise to frustration as they dealt with customer complaints during the recall period, highlighting the company's internal challenges [8]. - A company representative indicated that discussions are ongoing regarding the resumption of work once the 3C certification issues are resolved [7].

Group 1 - The company, Shenzhen Roma Technology Co., Ltd., has initiated a large-scale product recall involving over 490,000 mobile power products due to quality issues with battery cell materials [1] - The recall affects three main product models: PAC20-272, PAC20-392, and PLT20A-152, with PAC20-272 being the most affected, accounting for over 330,000 units, which is more than two-thirds of the total recall [1] - The identified issue is related to the quality of battery cell materials provided by upstream suppliers, which may lead to abnormal heating and potential fire risks under extreme usage conditions [1] Group 2 - The recall coincides with ongoing concerns regarding the safety of Roma power banks, as several universities in Beijing have banned their use, citing a higher risk of explosion compared to other brands [2] - In response to the university bans, the company has communicated with the Beijing Education Committee and has not received any official risk notifications, reaffirming its commitment to product responsibility [2] - The company offers affected users two solutions: a free replacement with a new mobile power bank of equal value or a direct refund [1]

Core Viewpoint - Apple has announced that a small number of Mac mini (2023) devices equipped with the M2 chip may fail to boot, affecting units produced between June 16, 2024, and November 23, 2024 [2] Group 1: Product Issues - Affected users can check their device's eligibility for free repair services using a serial number lookup tool [2] - Other Mac mini models are not included in this repair program, and any damage affecting repair must be resolved first [2] Group 2: Product Specifications - The Mac mini is a compact desktop computer, with the M2 version measuring 3.58 cm in thickness, 19.70 cm in width, and weighing only 1.18 kg [3] - It features an 8-core CPU, a 10-core GPU, and a 16-core neural engine, with a memory bandwidth of 100 GB/s [3] - The M2 model includes multiple ports: two Thunderbolt 4 ports, two USB-A ports, one HDMI port, one Gigabit Ethernet port (with an optional 10Gb Ethernet), and a 3.5mm headphone jack [3] Group 3: Market Performance - The Mac mini has gained popularity, with the M1 version capturing a leading market share in Japan, increasing from 15% to 27.1% within two weeks in 2020, a growth of over 14% [3] - In 2023, the top three mini desktop sales on JD.com were all Mac mini M2 models [3] Group 4: New Product Launch - In October of the previous year, Apple released a new Mac mini featuring M4 and M4 Pro chips, which is considered the smallest desktop model from Apple, measuring 12.7 cm x 12.7 cm x 4.97 cm [4] - The new Mac mini starts with 16GB of memory and has a starting price of 4499 yuan [4] Group 5: Future Uncertainty - Apple has not yet indicated whether the 2024 Mac mini will also experience the same boot issue [5]

Group 1: Company Developments - Dongfang Zhenxuan officially launched its self-operated sanitary napkins, with the first product being a "pure cotton surface sanitary napkin" aimed at safety and skin-friendliness [1][2] - The first batch of sanitary napkins includes two specifications: 240mm and 290mm, set to be available on the Dongfang Zhenxuan App on June 16 and across all official sales channels on June 18 [2] Group 2: Industry Issues - Multiple consumers reported being denied refunds for shoes purchased from the Staccato flagship store, with claims that the returned items were labeled as counterfeit [3][4] - A recent investigation revealed that some sun-protective clothing sold in the market does not meet national standards for UV protection, leading to the involvement of local market supervision authorities to halt production and sales of the implicated products [6][7][8] Group 3: Fraud Cases - Douyin e-commerce collaborated with police to dismantle a fraudulent charity scheme, resulting in the arrest of a suspect who allegedly profited over 690,000 yuan through deceptive "buy to donate" practices [5]

Core Viewpoint - The stock price of Kangtai Medical has plummeted significantly since its IPO, leading to a drastic reduction in market capitalization and shareholder value, prompting the major shareholder to initiate a share reduction plan [1][2][8]. Group 1: Stock Performance and Market Capitalization - Kangtai Medical's market capitalization has dropped from over 120 billion yuan to approximately 5.46 billion yuan, representing a decline of 95.58%, which equates to a loss of about 117 billion yuan [2][7]. - The stock price reached a peak of 307.03 yuan per share at the time of listing but has since fallen to a historical low of 13.97 yuan per share [2][7]. Group 2: Financial Performance - Since 2021, Kangtai Medical has experienced a continuous decline in net profit for four consecutive years, with a reported loss of 77.9 million yuan in 2024 [3][9]. - The company's revenue has also decreased, with 2021 revenue at 909 million yuan, down 35.15% year-on-year, and subsequent years showing further declines [10][11]. - Despite the financial downturn, the company has maintained high dividend payouts, totaling approximately 392 million yuan from 2020 to 2023, with the major shareholder receiving around 230 million yuan [4][12][13]. Group 3: Shareholder Actions - On May 8, 2024, the controlling shareholder, Hu Kun, announced plans to reduce his holdings by up to 12 million shares, which could yield approximately 168 million yuan [6][7]. - This marks Hu Kun's first instance of cashing out since the company's IPO, amidst a trend of frequent share reductions by executives and shareholders since 2021 [8]. Group 4: Product Quality and Legal Issues - In 2024, Kangtai Medical faced scrutiny over product quality, with several products failing to meet standards, resulting in a fine of 30,000 yuan [16][17]. - The company was also involved in a patent infringement lawsuit with Beijing Chao Si Electronic Technology, which was settled in December 2024 for 1 million USD [19][20][21].

Core Viewpoint - The National Medical Products Administration announced that two batches of toothpaste produced by Tianqi Family Chemical Industry Co., Ltd. were found to have excessive total bacterial counts, exceeding the limit by 37 times and 1279 times respectively [2][3]. Group 1: Product Quality Issues - Two batches of Tianqi toothpaste were reported with total bacterial counts of 19,000 CFU/g and 640,000 CFU/g, while the allowable limit is 500 CFU/g [3]. - The specific products involved are "Tianqi Anti-Bleeding Toothpaste (120g)" and "Tianqi Anti-Heat Toothpaste (Refreshing Wild Chrysanthemum Flavor) (165g)" [3]. Group 2: Company Response and Market Presence - As of April 28, the official flagship store of Tianqi did not list the involved products for sale [6]. - The company stated that they would relay the inquiry to a specialist, while the board secretary office of Zhongheng Group acknowledged awareness of the issue but required an email for further communication [7]. Group 3: Company Financial Performance - Zhongheng Group, the parent company of Tianqi, reported a revenue decline of 26.67% to 2.271 billion yuan and a net loss of 377 million yuan for 2024, marking a significant downturn from profitability [10]. - Tianqi Family Chemical Industry Co., Ltd. specifically recorded a net loss of 38.72 million yuan in 2024 [10]. Group 4: Ownership Structure - Zhongheng Group holds a 55.44% stake in Tianqi Family Chemical Industry, with the second-largest shareholder being Guangxi Guishun Investment Management Co., Ltd., holding 44.56% [7]. - Guangxi Investment Group Co., Ltd. also has a 25.62% stake in Zhongheng Group, indicating a strong connection to state-owned enterprises [8].